Taiki Hakozaki

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Taiki Hakozaki, Corentin Richard, Arielle Elkrief et al. · Cancer Immunology Research · 2020 · 300 citations

Life Sciences, Microbiology, Oncology +17

Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer

Taiki Hakozaki, Yusuke Okuma, Miwako Omori et al. · Oncology Letters · 2019 · 119 citations · Full text

Medicine, Oncology, Pharmacology +14

Switching administration of <scp>anti‐PD</scp>‐1 and <scp>anti‐PD‐L1</scp> antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review

Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai et al. · Thoracic Cancer · 2020 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 78 citations

Medicine, Oncology, Radiation Oncology +14

Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study

Miwako Omori, Yusuke Okuma, Taiki Hakozaki et al. · Molecular and Clinical Oncology · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +15